(Q54137490)

English

In vitro evaluation of sparfloxacin activity and spectrum against 24,940 pathogens isolated in the United States and Canada, the final analysis.

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

25 May 2018

http://europepmc.org/abstract/MED/9597392

In vitro evaluation of sparfloxacin activity and spectrum against 24,940 pathogens isolated in the United States and Canada, the final analysis. (English)

1 reference

Europe PubMed Central

PubMed publication ID

25 May 2018

http://europepmc.org/abstract/MED/9597392

0 references

1

object named as

R N Jones

1 reference

Europe PubMed Central

PubMed publication ID

25 May 2018

http://europepmc.org/abstract/MED/9597392

author name string

C H Ballow

2

1 reference

Europe PubMed Central

PubMed publication ID

25 May 2018

http://europepmc.org/abstract/MED/9597392

J J Schentag

3

1 reference

Europe PubMed Central

PubMed publication ID

25 May 2018

http://europepmc.org/abstract/MED/9597392

D M Johnson

4

1 reference

Europe PubMed Central

PubMed publication ID

25 May 2018

http://europepmc.org/abstract/MED/9597392

J A Deinhart

5

1 reference

Europe PubMed Central

PubMed publication ID

25 May 2018

http://europepmc.org/abstract/MED/9597392

publication date

1 May 1998

1 reference

Europe PubMed Central

PubMed publication ID

25 May 2018

http://europepmc.org/abstract/MED/9597392

Diagnostic Microbiology and Infectious Disease

1 reference

Europe PubMed Central

PubMed publication ID

25 May 2018

http://europepmc.org/abstract/MED/9597392

31

1 reference

Europe PubMed Central

PubMed publication ID

25 May 2018

http://europepmc.org/abstract/MED/9597392

1

1 reference

Europe PubMed Central

PubMed publication ID

25 May 2018

http://europepmc.org/abstract/MED/9597392

313-325

1 reference

Europe PubMed Central

PubMed publication ID

25 May 2018

http://europepmc.org/abstract/MED/9597392

Comparative safety and efficacy of sparfloxacin in the treatment of acute exacerbations of chronic obstructive pulmonary disease: a double-blind, randomised, parallel, multicentre study

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2897%2900247-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Sparfloxacin for the treatment of community-acquired pneumonia: a pooled data analysis of two studies

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2897%2900247-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Comparative in vitro assessment of sparfloxacin activity and spectrum using results from over 14,000 pathogens isolated at 190 medical centers in the USA. SPAR Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2897%2900247-2

7 January 2021

based on heuristic

inferred from DOI database lookup

In-vitro activity of sparfloxacin in comparison with currently available antimicrobials against respiratory tract pathogens

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2897%2900247-2

7 January 2021

based on heuristic

inferred from DOI database lookup

National survey of the in vitro spectrum of piperacillin-tazobactam tested against more than 40,000 aerobic clinical isolates from 236 medical centers.

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2897%2900247-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Canadian ciprofloxacin susceptibility study: comparative study from 15 medical centers. Canadian Ciprofloxacin Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2897%2900247-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Rapid development of ciprofloxacin resistance in methicillin-susceptible and -resistant Staphylococcus aureus.

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2897%2900247-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Emergence of drug-resistant pneumococcal infections in the United States

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2897%2900247-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Tetracycline and erythromycin resistance among clinical isolates of Branhamella catarrhalis

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2897%2900247-2

7 January 2021

based on heuristic

inferred from DOI database lookup

In vitro activity of BAY 12-8039, a novel 8-methoxyquinolone, compared to activities of six fluoroquinolones against Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2897%2900247-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Incomplete cross-resistance between ciprofloxacin and sparfloxacin in staphylococci, with a note on selection pressure due to clinical use of ciprofloxacin.

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2897%2900247-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Antistaphylococcal activities of sparfloxacin (CI-978; AT-4140), ofloxacin, and ciprofloxacin

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2897%2900247-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Sparfloxacin worldwide in vitro literature: isolate data available through 1994.

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2897%2900247-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Detection of quinolone resistance in Haemophilus spp.

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2897%2900247-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Lower respiratory tract infection due to ciprofloxacin resistant Moraxella catarrhalis

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2897%2900247-2

7 January 2021

based on heuristic

inferred from DOI database lookup

In vitro and in vivo antibacterial activities of levofloxacin (l-ofloxacin), an optically active ofloxacin

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2897%2900247-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Sparfloxacin versus cefuroxime axetil in the treatment of acute purulent sinusitis. Sinusitis Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2897%2900247-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility.

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2897%2900247-2

7 January 2021

based on heuristic

inferred from DOI database lookup

A 1994-95 survey of Haemophilus influenzae susceptibility to ten orally administered agents. A 187 clinical laboratory center sample in the United States

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2897%2900247-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Prevalence of important pathogens and antimicrobial activity of parenteral drugs at numerous medical centers in the United States, I. Study on the threat of emerging resistances: real or perceived? Fluoroquinolone Resistance Surveillance Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2897%2900247-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Interpretive criteria for disk diffusion susceptibility testing of sparfloxacin.

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2897%2900247-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Epidemiology, control and treatment of multiresistant pneumococci

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2897%2900247-2

7 January 2021

based on heuristic

inferred from DOI database lookup

In vitro activity of AT-4140 against clinical bacterial isolates

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2897%2900247-2

7 January 2021

based on heuristic

inferred from DOI database lookup

In vitro activity of AT-4140 against quinolone- and methicillin-resistant Staphylococcus aureus

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2897%2900247-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Oral empiric treatment of community-acquired pneumonia. A multicenter, double-blind, randomized study comparing sparfloxacin with roxithromycin. The Scandinavian Sparfloxacin Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2897%2900247-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Methicillin-resistant Staphylococcus aureus in U.S. hospitals, 1975-1991

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2897%2900247-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Comparative antistreptococcal activity of two newer fluoroquinolones, levofloxacin and sparfloxacin.

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2897%2900247-2

7 January 2021

based on heuristic

inferred from DOI database lookup

A multicenter study of the antimicrobial susceptibility of community-acquired lower respiratory tract pathogens in the United States, 1992-1994. The Alexander Project

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2897%2900247-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S0732-8893(97)00247-2

1 reference

Europe PubMed Central

PubMed publication ID

25 May 2018

http://europepmc.org/abstract/MED/9597392

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

25 May 2018

http://europepmc.org/abstract/MED/9597392

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q54137490&oldid=1940489267"